[China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46

Announced Date: 2024-10-29 (October 29, 2024)

Asset Name: CMG1A46

Licensor: Chimagen Biosciences  (China)

Licensee (Buyer): GSK plc

.

Asset Modality: T cell-engager (TCE)

Asset Target: CD19 and CD20-targeted, CD3

Potential Indication: B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.

Current Stage: Phase I clinical trials in leukaemia and lymphoma in both the US and China

.

Scope of Authority:

GSK will acquire full global rights of CMG1A46.

.

Payment Detail:

Chimagen will be eligible to receive

Upfront payment of $300 million,

Development and commercial milestone payments up to $550 million.

.

Link:

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline | GSK

.

Note:

Chinese Name of “Chimagen Biosciences“, “恩沐生物”